Scarica l'app Stockscreener
1.61
10.06%
-0.18
Dopo l'orario di chiusura:
1.66
0.05
+3.11%
Precedente Chiudi:
$1.79
Aprire:
$1.7
Volume 24 ore:
1.37M
Relative Volume:
1.20
Capitalizzazione di mercato:
$209.84M
Reddito:
-
Utile/perdita netta:
$-217.44M
Rapporto P/E:
-0.7419
EPS:
-2.17
Flusso di cassa netto:
$-205.20M
1 W Prestazione:
-19.50%
1M Prestazione:
-27.96%
6M Prestazione:
-52.79%
1 anno Prestazione:
-72.24%
Intervallo 1D:
$1.5846
$1.71
Intervallo di 1 settimana:
$1.5846
$2.11
Portata 52W:
$1.5846
$8.27
Prime Medicine Inc Stock (PRME) Company Profile
Nome
Prime Medicine Inc
Settore
Industria
Telefono
617-465-0013
Indirizzo
60 FIRST ST., CAMBRIDGE
Confronta PRME con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
1.61 | 209.84M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-05-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-22 | Iniziato | Chardan Capital Markets | Buy |
| 2024-04-08 | Iniziato | TD Cowen | Buy |
| 2024-04-03 | Iniziato | Wedbush | Outperform |
| 2024-01-16 | Downgrade | Stifel | Buy → Hold |
| 2023-12-08 | Iniziato | Citigroup | Neutral |
| 2023-10-09 | Iniziato | BMO Capital Markets | Outperform |
| 2023-07-31 | Iniziato | Guggenheim | Buy |
| 2023-04-18 | Iniziato | Stifel | Buy |
| 2022-11-14 | Iniziato | Goldman | Neutral |
| 2022-11-14 | Iniziato | JP Morgan | Overweight |
| 2022-11-14 | Iniziato | Jefferies | Buy |
| 2022-11-14 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prime Medicine Inc Borsa (PRME) Ultime notizie
There is no way Prime Medicine Inc (PRME) can keep these numbers up - Sete News
Charles Schwab Investment Management Inc. Acquires 20,614 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of “Buy” from Analysts - The AM Reporter
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Analysts Set Prime Medicine, Inc. (NYSE:PRME) Target Price at $13.38 - Defense World
Wedbush Forecasts Prime Medicine FY2029 Earnings - Defense World
Chardan Capital Forecasts Strong Price Appreciation for Prime Medicine (NYSE:PRME) Stock - Defense World
Prime Medicine (NYSE:PRME) Earns “Buy” Rating from HC Wainwright - Defense World
Why Prime Medicine Stock Was Climbing Higher This Week - Yahoo
Prime Medicine price target raised to $16 from $15 at Chardan - TipRanks
Chardan Raises Price Target on Prime Medicine to $16 From $15, Keeps Buy Rating -March 20, 2025 at 06:45 am EDT - MarketScreener
Why Prime Medicine Stock Is Soaring Today - Yahoo
Prime Medicine’s SWOT analysis: gene editing firm’s stock faces pivotal year - Investing.com India
Prime Medicine’s SWOT analysis: gene editing firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
Prime Medicine announces new α1-antitrypsin deficiency program - BioWorld MedTech
Prime Medicine, Inc.: Promising Future in Gene Editing with Innovative AATD Program and Strategic Growth Potential - TipRanks
H.C. Wainwright maintains Buy on Prime Medicine stock, $10 target By Investing.com - Investing.com Canada
Prime Medicine, Inc.: Innovative Prime Editing Platform Targets Unmet Medical Needs with Promising Preclinical Results - TipRanks
Prime Medicine (NYSE:PRME) Given “Outperform” Rating at Wedbush - Defense World
Prime Medicine’s Promising Advancements in Liver-Targeting AATD Program with Prime Editing Technology - TipRanks
Prime Medicine advances AATD gene editing therapy - Investing.com India
Prime Medicine, Inc.: Innovative Prime Editing Technology and Promising Preclinical Results Drive Buy Rating - TipRanks
Prime Medicine Advances AATD Program With Prime Editing For Potential Curative Treatment - Nasdaq
Wedbush Adjusts Prime Medicine Price Target to $13 From $12, Maintains Outperform Rating - Marketscreener.com
Prime sets sights on liver, lung disease as next target for its gene editing tech - BioPharma Dive
Prime Medicine unveils program for treatment of AATD - TipRanks
Prime Medicine Advances AATD Program with Promising Preclinical Results - TipRanks
Prime Medicine Launches Preclinical Program for Liver Treatments -March 18, 2025 at 07:34 am EDT - Marketscreener.com
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewswire
Revolutionary Gene Editing Breakthrough: Prime Medicine's AATD Treatment Shows 95% Protein Restoration - StockTitan
Prime Medicine, Inc.: Strategic Advancements and Promising Financial Outlook Drive Buy Rating - TipRanks
Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta - Benzinga
Chardan Capital Forecasts Prime Medicine FY2025 Earnings - Defense World
Prime Medicine’s SWOT analysis: gene editing firm’s stock poised for pivotal year By Investing.com - Investing.com South Africa
Prime Medicine’s SWOT analysis: gene editing firm’s stock poised for pivotal year - Investing.com
Prime Medicine Inc (PRME)’s Market Momentum: Closing Strong at 2.40, Up 4.35 - The Dwinnex
Is Prime Medicine Inc (NASDAQ: PRME) A Great Stock To Invest In? - Stocks Register
Oppenheimer & Co. Inc. Decreases Stake in Prime Medicine, Inc. (NYSE:PRME) - Defense World
HC Wainwright Expects Increased Earnings for Prime Medicine - Defense World
Citizens JMP maintains $10 target on Prime Medicine stock - Investing.com India
Prime Medicine (NYSE:PRME) Given “Buy” Rating at Chardan Capital - Defense World
Prime Medicine’s Advancements and Financial Strength Support Buy Rating Amid Promising Developments in Gene Editing and Rare Diseases - TipRanks
Prime Medicine, Inc.: Promising Gene Editing Developments and Strong Financial Position Justify Buy Rating - TipRanks
Prime Medicine’s (PRME) “Outperform” Rating Reiterated at Wedbush - Defense World
ARK Investment Management LLC Reduces Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - MarketBeat
Prime Medicine Reports 2024 Financial Results and Progress - TipRanks
Prime Medicine, Inc. SEC 10-K Report - TradingView
Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates - The Manila Times
Can Prime Medicine's $204M Cash Boost Fuel Its Gene Editing Breakthrough? Clinical Data Coming in 2025 - StockTitan
Prime Medicine (NYSE:PRME) vs. Bio-Techne (NASDAQ:TECH) Critical Analysis - Defense World
News: CMN Weekly (28 February 2025)Your Weekly CRISPR Medicine News - CRISPR Medicine News
Prime Medicine Inc Azioni (PRME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):